CACLP - The largest IVD Expo & Conference

Illumina, AstraZeneca, Breast Cancer Canada Partner on Screening, Detection Grants

Industry news | 19 June, 2023 | CACLP

Original from: genomeweb

 

Breast Cancer Canada said on Thursday that it has launched a new grant program in collaboration with AstraZeneca Canada and Illumina. 

 

Breast Cancer Canada and AstraZeneca will award C$200,000 (US$151,381) to Canadian research teams to advance screening and detection of breast cancer. Illumina will provide in-kind donations of sequencing consumables.

 

The partners seek grantees using precision medicine-based technologies, including artificial intelligence and machine learning. The submission period opens July 3, 2023. 

 

"By investing in Canadian breast cancer screening research, Breast Cancer Canada and AstraZeneca Canada are advancing innovation technology to diagnose the disease earlier, faster, and ahead of symptoms. We are looking for research teams to revolutionize breast cancer detection," said Kimberly Carson, CEO of Breast Cancer Canada. "The progress we seek will address higher quality, less invasive, and more accessible test techniques for Canadians."

 

Breast Cancer Canada also announced the recipients of its annual Precision Oncology Research Grants. The program awarded C$75,000 each to: Saima Hassan of the University of Montreal Hospital Research center to study the immune landscape to predict response to immunotherapy and PARP inhibition; Katarzyna Jerzak of Sunnybrook Odette Cancer Centre to identify microRNA biomarkers for breast to brain metastasis; Joanne Kotsopoulos of the University of Toronto to study improving long-term outcomes of BRCA1-associated breast cancer; and Hermann Nabi of the Quebec City University Hospital Research Centre for personalized risk-stratified breast cancer follow-up care. 

 

Meanwhile, Luc Sabourin of Ottawa Hospital Research Institute and Mohammad Akbari of the University of Toronto were each awarded C$50,000 to study targeting Sox10 activity in HER2+ breast cancer and gene expression profiling in young-onset ER+/HER2- breast cancer patients, respectively.

Source: Illumina, AstraZeneca, Breast Cancer Canada Partner on Screening, Detection Grants

 

Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference